Puma Biotechnology, Inc.
PBYINASDAQHealthcare● Active
$6.85
$-0.18(-2.56%)
Market Cap$348661274
P/E Ratio—
52W High$7.9
52W Low$3.03
Puma Biotechnology, Inc. (PBYI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PBYI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.23B | $0.23B | $0.24B | $0.23B | $0.25B |
| Cost of Revenue | $0.06B | $0.06B | $0.06B | $0.06B | $0.06B |
| Gross Profit | $0.17B | $0.17B | $0.17B | $0.17B | $0.19B |
| Gross Margin %(computed) | 74.53% | 72.06% | 73.40% | 75.84% | 74.84% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.05B | $0.05B | $0.05B | $0.07B |
| G&A Expenses | $0.07B | $0.08B | $0.09B | $0.09B | $0.12B |
| Total Operating Expenses | $0.13B | $0.14B | $0.14B | $0.15B | $0.19B |
| Operating Income | $0.04B | $0.03B | $0.03B | $0.02B | $0.00B |
| Operating Margin %(computed) | 16.33% | 13.44% | 13.85% | 10.40% | 0.51% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | $0.04B | $0.02B | $0.02B | $0.00B | ($0.03B) |
| Income Tax Expense | $0.00B | ($0.01B) | $0.00B | $0.00B | $0.00B |
| Net Income | $0.03B | $0.03B | $0.02B | $0.00B | ($0.03B) |
| Net Margin %(computed) | 13.62% | 13.14% | 9.16% | 0.00% | -11.51% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.62 | $0.62 | $0.46 | $0.02 | $-0.72 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.04B | 0.04B |
| EBITDA | $0.05B | $0.05B | $0.05B | $0.02B | ($0.00B) |
| EBITDA Margin %(computed) | 23.36% | 20.86% | 20.17% | 9.60% | -1.85% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Puma Biotechnology, Inc. data
About Puma Biotechnology, Inc. (PBYI) Income Statement
Puma Biotechnology, Inc. (PBYI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PBYI reported revenue of $0.23B, gross profit of $0.17B (gross margin 74.53%), and net income of $0.03B — a net profit margin of 13.62%.
Frequently asked questions
PBYI · 4 questionsPuma Biotechnology, Inc. (PBYI) reported revenue of $0.23B for 2025, down 0.9% year-over-year.
PBYI revenuePBYI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09